Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology
The guidelines also highlight endoscopic retrograde cholangiopancreatography (ERCP), a procedure that combines an upper endoscopy and x-rays to treat problems in the bile and pancreatic ducts. According to the guidelines, patients with acute pancreatitis and concurrent acute cholangitis should undergo ERCP within 24 hours of admission. It is also important to note that the prevalence of acute pancreatitis has been increasing in recent years. “Although the case fatality rate for acute pancreatitis has decreased over time, the overall population mortality rate for acute pancreatitis has remained unchanged,” state the guidelines. To listen to the podcast of Dr. Tenner discussing the guidelines, visit: http://gi.org/physician-resources/podcasts/the-american-journal-of-gastroenterology-author-podcasts/. About the American College of Gastroenterology Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of more than 12,000 individuals from 80 countries. The College is committed to serving the clinically oriented digestive disease specialist through its emphasis on scholarly practice, teaching and research. The mission of the College is to serve the evolving needs of physicians in the delivery of high quality, scientifically sound, humanistic, ethical, and cost-effective health care to gastroenterology patients. http://www.gi.org About The American Journal of Gastroenterology The American Journal of Gastroenterology is published on behalf of the American College of Gastroenterology by Nature Publishing Group. As the leading clinical journal covering gastroenterology and hepatology, The American Journal of Gastroenterology provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. The Co-Editors-in-Chief are William D.
Patients who experience dyspnea should inform their doctor. Interaction: It is unlikely that lubiprostone will cause interactions with other medications. Pregnancy and lactation: AMITIZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Breast-feeding during use of AMITIZA is not recommended. Side effects: Most common in clinical studies (in over 10% of patients) were nausea, diarrhoea and headaches. Other side effects (in over 1% of patients) were abdominal pain, abdominal distension, flatulence, vomiting, dizziness, peripheral oedema, fatigue, chest discomfort or pain, dyspnea, abdominal discomfort, dyspepsia, and dry mouth. Although dyspnea is not classified as severe, some patients discontinued treatment. Packaging: Soft capsules in HDPE bottles of 56 (B) with seal and rayon filler. State of information: May 2013. Sucampo AG, Zug. About Sucampo Sucampo AG, based in Zug, Switzerland, is a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman, Chief Executive Officer, Chief Scientific Officer, and co-founder.